<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;ff=20230720062954&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;ff=20230720062954&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Thu, 20 Jul 2023 10:29:55 +0000</lastbuilddate>
<pubDate>Wed, 19 Jul 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Reply: Diagnosing Prosthesis-Patient Mismatch Without Real Echocardiographic Assessments: Are We Studying This Incorrectly?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37468194/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720062954&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Jul 25;82(4):e29. doi: 10.1016/j.jacc.2023.05.029.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37468194/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720062954&v=2.17.9.post6+86293ac">37468194</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.029>10.1016/j.jacc.2023.05.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37468194</guid>
<pubDate>Wed, 19 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Michael Dismorr</dc:creator>
<dc:creator>Natalie Glaser</dc:creator>
<dc:creator>Anders Franco-Cereceda</dc:creator>
<dc:creator>Ulrik Sartipy</dc:creator>
<dc:date>2023-07-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Diagnosing Prosthesis-Patient Mismatch Without Real Echocardiographic Assessments: Are We Studying This Incorrectly?</dc:title>
<dc:identifier>pmid:37468194</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.029</dc:identifier>
</item>
<item>
<title>Diagnosing Prosthesis-Patient Mismatch Without Real Echocardiographic Assessments: Are We Studying This Incorrectly?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37468193/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720062954&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Jul 25;82(4):e27. doi: 10.1016/j.jacc.2023.05.027.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37468193/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720062954&v=2.17.9.post6+86293ac">37468193</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.027>10.1016/j.jacc.2023.05.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37468193</guid>
<pubDate>Wed, 19 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Bo Yang</dc:creator>
<dc:creator>Edward P Chen</dc:creator>
<dc:creator>Gorav Ailawadi</dc:creator>
<dc:creator>Michael J Reardon</dc:creator>
<dc:creator>G Michael Deeb</dc:creator>
<dc:date>2023-07-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Diagnosing Prosthesis-Patient Mismatch Without Real Echocardiographic Assessments: Are We Studying This Incorrectly?</dc:title>
<dc:identifier>pmid:37468193</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.027</dc:identifier>
</item>
<item>
<title>Fall Outcomes With Left Atrial Appendage Occlusion vs Direct Oral Anticoagulants for Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37468192/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720062954&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Jul 25;82(4):379-381. doi: 10.1016/j.jacc.2023.05.032.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37468192/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720062954&v=2.17.9.post6+86293ac">37468192</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.032>10.1016/j.jacc.2023.05.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37468192</guid>
<pubDate>Wed, 19 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Wenjun Deng</dc:creator>
<dc:creator>Moussa Mansour</dc:creator>
<dc:creator>Bo Song</dc:creator>
<dc:creator>Haiman Hou</dc:creator>
<dc:creator>Kai Liu</dc:creator>
<dc:creator>YuMing Xu</dc:creator>
<dc:creator>David McMullin</dc:creator>
<dc:creator>Ferdinando S Buonanno</dc:creator>
<dc:creator>Eng H Lo</dc:creator>
<dc:creator>MingMing Ning</dc:creator>
<dc:date>2023-07-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Fall Outcomes With Left Atrial Appendage Occlusion vs Direct Oral Anticoagulants for Atrial Fibrillation</dc:title>
<dc:identifier>pmid:37468192</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.032</dc:identifier>
</item>
<item>
<title>Development of the Implantable Cardioverter-Defibrillator: JACC Historical Breakthroughs in Perspective</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37468191/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720062954&amp;v=2.17.9.post6+86293ac
      <description>Implantable cardioverter-defibrillators (ICDs) represent transformational technology, arguably the most significant advance in cardiovascular medicine in 50 years. The vision and determination of pioneers Mirowski and Mower was fundamental to this monumental achievement, working with limited resources and confronted by skepticism/criticism from medical establishment. The inventors were followed >;35 years in which a multitude of innovative clinical scientists and engineers introduced...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Jul 25;82(4):353-373. doi: 10.1016/j.jacc.2023.04.056.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Implantable cardioverter-defibrillators (ICDs) represent transformational technology, arguably the most significant advance in cardiovascular medicine in 50 years. The vision and determination of pioneers Mirowski and Mower was fundamental to this monumental achievement, working with limited resources and confronted by skepticism/criticism from medical establishment. The inventors were followed >;35 years in which a multitude of innovative clinical scientists and engineers introduced technological advances leading to the sophisticated devices in practice today. A pivotal patient experiment with automated termination of ventricular fibrillation (1980) led to U.S. Food and Drug Administration approval. Transvenous lead systems converted ICDs from thoracotomy-based secondary prevention to primary prevention of sudden death devices in countless patients worldwide. ICD acceptance was solidified by prospective randomized controlled trials showing reduced mortality superior to antiarrhythmic drugs. ICDs eventually expanded from coronary disease to inherited arrhythmia conditions (eg, hypertrophic cardiomyopathy). The ICD breakthrough story demonstrates how significant progress is possible in medicine against all odds, given fearless imagination to pursue novel ideas that conflict with accepted wisdom.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37468191/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720062954&v=2.17.9.post6+86293ac">37468191</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.04.056>10.1016/j.jacc.2023.04.056</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37468191</guid>
<pubDate>Wed, 19 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Barry J Maron</dc:creator>
<dc:creator>N A Mark Estes</dc:creator>
<dc:creator>Ethan J Rowin</dc:creator>
<dc:creator>Martin S Maron</dc:creator>
<dc:creator>Matthew R Reynolds</dc:creator>
<dc:date>2023-07-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Development of the Implantable Cardioverter-Defibrillator: JACC Historical Breakthroughs in Perspective</dc:title>
<dc:identifier>pmid:37468191</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.04.056</dc:identifier>
</item>
<item>
<title>Omega-3 Fatty Acids and Risk for Atrial Fibrillation: Big Fish or Small Fry?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37468190/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720062954&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Jul 25;82(4):350-352. doi: 10.1016/j.jacc.2023.05.026.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37468190/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720062954&v=2.17.9.post6+86293ac">37468190</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.026>10.1016/j.jacc.2023.05.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37468190</guid>
<pubDate>Wed, 19 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Christie M Ballantyne</dc:creator>
<dc:creator>Xiaoming Jia</dc:creator>
<dc:date>2023-07-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Omega-3 Fatty Acids and Risk for Atrial Fibrillation: Big Fish or Small Fry?</dc:title>
<dc:identifier>pmid:37468190</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.026</dc:identifier>
</item>
<item>
<title>Omega-3 Fatty Acid Biomarkers and Incident Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37468189/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720062954&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In vivo levels of omega-3 fatty acids including EPA, DPA, DHA, and EPA+DHA were not associated with increased risk of incident AF. Our data suggest the safety of habitual dietary intakes of omega-3 fatty acids with respect to AF risk. Coupled with the known benefits of these fatty acids in the prevention of adverse coronary events, our study suggests that current dietary guidelines recommending fish/omega-3 fatty acid consumption can be maintained.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Jul 25;82(4):336-349. doi: 10.1016/j.jacc.2023.05.024.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The relationship between omega-3 fatty acids and atrial fibrillation (AF) remains controversial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to determine the prospective associations of blood or adipose tissue levels of eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA) with incident AF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used participant-level data from a global consortium of 17 prospective cohort studies, each with baseline data on blood or adipose tissue omega-3 fatty acid levels and AF outcomes. Each participating study conducted a de novo analyses using a prespecified analytical plan with harmonized definitions for exposures, outcome, covariates, and subgroups. Associations were pooled using inverse-variance weighted meta-analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 54,799 participants from 17 cohorts, 7,720 incident cases of AF were ascertained after a median 13.3 years of follow-up. In multivariable analysis, EPA levels were not associated with incident AF, HR per interquintile range (ie, the difference between the 90th and 10th percentiles) was 1.00 (95% CI: 0.95-1.05). HRs for higher levels of DPA, DHA, and EPA+DHA, were 0.89 (95% CI: 0.83-0.95), 0.90 (95% CI: 0.85-0.96), and 0.93 (95% CI: 0.87-0.99), respectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In vivo levels of omega-3 fatty acids including EPA, DPA, DHA, and EPA+DHA were not associated with increased risk of incident AF. Our data suggest the safety of habitual dietary intakes of omega-3 fatty acids with respect to AF risk. Coupled with the known benefits of these fatty acids in the prevention of adverse coronary events, our study suggests that current dietary guidelines recommending fish/omega-3 fatty acid consumption can be maintained.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37468189/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720062954&v=2.17.9.post6+86293ac">37468189</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.024>10.1016/j.jacc.2023.05.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37468189</guid>
<pubDate>Wed, 19 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Frank Qian</dc:creator>
<dc:creator>Nathan Tintle</dc:creator>
<dc:creator>Paul N Jensen</dc:creator>
<dc:creator>Rozenn N Lemaitre</dc:creator>
<dc:creator>Fumiaki Imamura</dc:creator>
<dc:creator>Tobias Rudholm Feldreich</dc:creator>
<dc:creator>Sarah Oppeneer Nomura</dc:creator>
<dc:creator>Weihua Guan</dc:creator>
<dc:creator>Federica Laguzzi</dc:creator>
<dc:creator>Eunjung Kim</dc:creator>
<dc:creator>Jyrki K Virtanen</dc:creator>
<dc:creator>Marinka Steur</dc:creator>
<dc:creator>Christian S Bork</dc:creator>
<dc:creator>Yoichiro Hirakawa</dc:creator>
<dc:creator>Michelle L O'Donoghue</dc:creator>
<dc:creator>Aleix Sala-Vila</dc:creator>
<dc:creator>Andres V Ardisson Korat</dc:creator>
<dc:creator>Qi Sun</dc:creator>
<dc:creator>Eric B Rimm</dc:creator>
<dc:creator>Bruce M Psaty</dc:creator>
<dc:creator>Susan R Heckbert</dc:creator>
<dc:creator>Nita G Forouhi</dc:creator>
<dc:creator>Nicholas J Wareham</dc:creator>
<dc:creator>Matti Marklund</dc:creator>
<dc:creator>Ulf Risérus</dc:creator>
<dc:creator>Lars Lind</dc:creator>
<dc:creator>Johan Ärnlöv</dc:creator>
<dc:creator>Parveen Garg</dc:creator>
<dc:creator>Michael Y Tsai</dc:creator>
<dc:creator>James Pankow</dc:creator>
<dc:creator>Jeffrey R Misialek</dc:creator>
<dc:creator>Bruna Gigante</dc:creator>
<dc:creator>Karin Leander</dc:creator>
<dc:creator>Julie A Pester</dc:creator>
<dc:creator>Christine M Albert</dc:creator>
<dc:creator>Maryam Kavousi</dc:creator>
<dc:creator>Arfan Ikram</dc:creator>
<dc:creator>Trudy Voortman</dc:creator>
<dc:creator>Erik B Schmidt</dc:creator>
<dc:creator>Toshiharu Ninomiya</dc:creator>
<dc:creator>David A Morrow</dc:creator>
<dc:creator>Antoni Bayés-Genís</dc:creator>
<dc:creator>James H O'Keefe</dc:creator>
<dc:creator>Kwok Leung Ong</dc:creator>
<dc:creator>Jason H Y Wu</dc:creator>
<dc:creator>Dariush Mozaffarian</dc:creator>
<dc:creator>William S Harris</dc:creator>
<dc:creator>David S Siscovick</dc:creator>
<dc:creator>Fatty Acids and Outcomes Research Consortium (FORCE)</dc:creator>
<dc:date>2023-07-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Omega-3 Fatty Acid Biomarkers and Incident Atrial Fibrillation</dc:title>
<dc:identifier>pmid:37468189</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.024</dc:identifier>
</item>
<item>
<title>Epicardial Adipose-Derived miR92a-3p: Stress Reduction Therapy?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37468188/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720062954&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Jul 25;82(4):333-335. doi: 10.1016/j.jacc.2023.05.030.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37468188/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720062954&v=2.17.9.post6+86293ac">37468188</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.030>10.1016/j.jacc.2023.05.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37468188</guid>
<pubDate>Wed, 19 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Timothy P Fitzgibbons</dc:creator>
<dc:date>2023-07-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Epicardial Adipose-Derived miR92a-3p: Stress Reduction Therapy?</dc:title>
<dc:identifier>pmid:37468188</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.030</dc:identifier>
</item>
<item>
<title>Role of Human Epicardial Adipose Tissue-Derived miR-92a-3p in Myocardial Redox State</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37468187/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720062954&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: EAT-derived miRNAs exert paracrine effects on the human heart. Indeed miR-92a-3p suppresses the wingless-type MMTV integration site family, member 5a/Rac1/NADPH oxidase axis and improves the myocardial redox state. EAT-derived miR-92a-3p is related to improved clinical outcomes and is a rational therapeutic target for the prevention and treatment of obesity-related heart disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Jul 25;82(4):317-332. doi: 10.1016/j.jacc.2023.05.031.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Visceral obesity is directly linked to increased cardiovascular risk, including heart failure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study explored the ability of human epicardial adipose tissue (EAT)-derived microRNAs (miRNAs) to regulate the myocardial redox state and clinical outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This study screened for miRNAs expressed and released from human EAT and tested for correlations with the redox state in the adjacent myocardium in paired EAT/atrial biopsy specimens from patients undergoing cardiac surgery. Three miRNAs were then tested for causality in an in vitro model of cardiomyocytes. At a clinical level, causality/directionality were tested using genome-wide association screening, and the underlying mechanisms were explored using human biopsy specimens, as well as overexpression of the candidate miRNAs and their targets in vitro and in vivo using a transgenic mouse model. The final prognostic value of the discovered targets was tested in patients undergoing cardiac surgery, followed up for a median of 8 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: EAT miR-92a-3p was related to lower oxidative stress in human myocardium, a finding confirmed by using genetic regulators of miR-92a-3p in the human heart and EAT. miR-92a-3p reduced nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase-derived superoxide (O<sub>2</sub><sup>.-</sup>) by targeting myocardial expression of WNT5A, which regulated Rac1-dependent activation of NADPH oxidases. Finally, high miR-92a-3p levels in EAT were independently related with lower risk of adverse cardiovascular events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: EAT-derived miRNAs exert paracrine effects on the human heart. Indeed miR-92a-3p suppresses the wingless-type MMTV integration site family, member 5a/Rac1/NADPH oxidase axis and improves the myocardial redox state. EAT-derived miR-92a-3p is related to improved clinical outcomes and is a rational therapeutic target for the prevention and treatment of obesity-related heart disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37468187/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720062954&v=2.17.9.post6+86293ac">37468187</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.031>10.1016/j.jacc.2023.05.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37468187</guid>
<pubDate>Wed, 19 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Maria Cristina Carena</dc:creator>
<dc:creator>Ileana Badi</dc:creator>
<dc:creator>Murray Polkinghorne</dc:creator>
<dc:creator>Ioannis Akoumianakis</dc:creator>
<dc:creator>Costas Psarros</dc:creator>
<dc:creator>Elizabeth Wahome</dc:creator>
<dc:creator>Christos P Kotanidis</dc:creator>
<dc:creator>Nadia Akawi</dc:creator>
<dc:creator>Alexios S Antonopoulos</dc:creator>
<dc:creator>Jagat Chauhan</dc:creator>
<dc:creator>Rana Sayeed</dc:creator>
<dc:creator>George Krasopoulos</dc:creator>
<dc:creator>Vivek Srivastava</dc:creator>
<dc:creator>Shakil Farid</dc:creator>
<dc:creator>Nicholas Walcot</dc:creator>
<dc:creator>Gillian Douglas</dc:creator>
<dc:creator>Keith M Channon</dc:creator>
<dc:creator>Barbara Casadei</dc:creator>
<dc:creator>Charalambos Antoniades</dc:creator>
<dc:date>2023-07-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Role of Human Epicardial Adipose Tissue-Derived miR-92a-3p in Myocardial Redox State</dc:title>
<dc:identifier>pmid:37468187</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.031</dc:identifier>
</item>
<item>
<title>The Interplay of Complete Revascularization and Angina: More Is More?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37468186/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720062954&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Jul 25;82(4):314-316. doi: 10.1016/j.jacc.2023.06.002.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37468186/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720062954&v=2.17.9.post6+86293ac">37468186</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.002>10.1016/j.jacc.2023.06.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37468186</guid>
<pubDate>Wed, 19 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Yousif Ahmad</dc:creator>
<dc:creator>Eric J Velazquez</dc:creator>
<dc:date>2023-07-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Interplay of Complete Revascularization and Angina: More Is More?</dc:title>
<dc:identifier>pmid:37468186</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.002</dc:identifier>
</item>
<item>
<title>Complete Revascularization and Angina-Related Health Status in the ISCHEMIA Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37468185/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720062954&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Among patients with CCD in ISCHEMIA, health status improved more with CR compared with ICR or CON, particularly in those with frequent angina. Anatomic and functional CR provided comparable improvements in quality of life. (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches [ISCHEMIA]; NCT01471522).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Jul 25;82(4):295-313. doi: 10.1016/j.jacc.2023.05.025.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The impact of complete revascularization (CR) on angina-related health status (symptoms, function, quality of life) in chronic coronary disease (CCD) has not been well studied.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: Among patients with CCD randomized to invasive (INV) vs conservative (CON) management in ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches), we compared the following: 1) the impact of anatomic and functional CR on health status compared with incomplete revascularization (ICR); and 2) the predicted impact of achieving CR in all INV patients compared with CON.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Multivariable regression adjusting for patient characteristics was used to compare 12-month health status after independent core laboratory-defined CR vs ICR in INV patients who underwent revascularization. Propensity-weighted modeling was then performed to estimate the treatment effect had CR or ICR been achieved in all INV patients, compared with CON.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Anatomic and functional CR were achieved in 43.3% and 57.8% of 1,641 INV patients, respectively. Among revascularized patients, CR was associated with improved Seattle Angina Questionnaire Angina Frequency compared with ICR after adjustment for baseline differences. After modeling CR and ICR in all INV patients, patients with CR and ICR each had greater improvements in health status than CON, with better health status with CR than ICR. The projected benefits of CR were most pronounced in patients with baseline daily/weekly angina and not seen in those with no angina.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among patients with CCD in ISCHEMIA, health status improved more with CR compared with ICR or CON, particularly in those with frequent angina. Anatomic and functional CR provided comparable improvements in quality of life. (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches [ISCHEMIA]; NCT01471522).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37468185/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720062954&v=2.17.9.post6+86293ac">37468185</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.025>10.1016/j.jacc.2023.05.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37468185</guid>
<pubDate>Wed, 19 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Kreton Mavromatis</dc:creator>
<dc:creator>Philip G Jones</dc:creator>
<dc:creator>Ziad A Ali</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Grace M Rhodes</dc:creator>
<dc:creator>Sripal Bangalore</dc:creator>
<dc:creator>Sean O'Brien</dc:creator>
<dc:creator>Philippe Genereux</dc:creator>
<dc:creator>Jennifer Horst</dc:creator>
<dc:creator>Ovidiu Dressler</dc:creator>
<dc:creator>Shaun Goodman</dc:creator>
<dc:creator>Karen Alexander</dc:creator>
<dc:creator>Anoop Mathew</dc:creator>
<dc:creator>Jiyan Chen</dc:creator>
<dc:creator>Balram Bhargava</dc:creator>
<dc:creator>Amar Uxa</dc:creator>
<dc:creator>William E Boden</dc:creator>
<dc:creator>Daniel B Mark</dc:creator>
<dc:creator>Harmony R Reynolds</dc:creator>
<dc:creator>David J Maron</dc:creator>
<dc:creator>Judith S Hochman</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>ISCHEMIA Research Group</dc:creator>
<dc:date>2023-07-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Complete Revascularization and Angina-Related Health Status in the ISCHEMIA Trial</dc:title>
<dc:identifier>pmid:37468185</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.025</dc:identifier>
</item>
<item>
<title>Tricuspid Transcatheter Repair: Edging Toward Prime Time?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37468184/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720062954&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Jul 25;82(4):292-294. doi: 10.1016/j.jacc.2023.05.028.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37468184/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720062954&v=2.17.9.post6+86293ac">37468184</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.028>10.1016/j.jacc.2023.05.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37468184</guid>
<pubDate>Wed, 19 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Josep Rodés-Cabau</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:date>2023-07-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Tricuspid Transcatheter Repair: Edging Toward Prime Time?</dc:title>
<dc:identifier>pmid:37468184</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.028</dc:identifier>
</item>
<item>
<title>Tracking Treatment Response in Cardiac Light-Chain Amyloidosis With Native T1 Mapping</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37466990/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720062954&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: Changes in native T1 in response to treatment, reflecting a composite of changes in T2 and ECV, are associated with in changes in traditional markers of cardiac response and associated with mortality. However, as a single-center study, these results require external validation in a larger cohort.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Jul 19. doi: 10.1001/jamacardio.2023.2010. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Cardiac magnetic resonance (CMR) imaging-derived extracellular volume (ECV) mapping, generated from precontrast and postcontrast T1, accurately determines treatment response in cardiac light-chain amyloidosis. Native T1 mapping, which can be derived without the need for contrast, has demonstrated accuracy in diagnosis and prognostication, but it is unclear whether serial native T1 measurements could also track the cardiac treatment response.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess whether native T1 mapping can measure the cardiac treatment response and the association between changes in native T1 and prognosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This single-center cohort study evaluated patients diagnosed with cardiac light-chain amyloidosis (January 2016 to December 2020) who underwent CMR scans at diagnosis and a repeat scan following chemotherapy. Analysis took place between January 2016 and October 2022.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Comparison of biomarkers and cardiac imaging parameters between patients with a reduced, stable, or increased native T1 and association between changes in native T1 and mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study comprised 221 patients (mean [SD] age, 64.7 [10.6] years; 130 male [59%]). At 6 months, 183 patients (mean [SD] age, 64.8 [10.5] years; 110 male [60%]) underwent repeat CMR imaging. Reduced native T1 of 50 milliseconds or more occurred in 8 patients (4%), all of whom had a good hematological response; by contrast, an increased native T1 of 50 milliseconds or more occurred in 42 patients (23%), most of whom had a poor hematological response (27 [68%]). At 12 months, 160 patients (mean [SD] age, 63.8 [11.1] years; 94 male [59%]) had a repeat CMR scan. A reduced native T1 occurred in 24 patients (15%), all of whom had a good hematological response, and was associated with a reduction in N-terminal pro-brain natriuretic peptide (median [IQR], 2638 [913-5767] vs 423 [128-1777] ng/L; P &lt; .001), maximal wall thickness (mean [SD], 14.8 [3.6] vs 13.6 [3.9] mm; P = .009), and E/e' (mean [SD], 14.9 [6.8] vs 12.0 [4.0]; P = .007), improved longitudinal strain (mean [SD], -14.8% [4.0%] vs -16.7% [4.0%]; P = .004), and reduction in both myocardial T2 (mean [SD], 52.3 [2.9] vs 49.4 [2.0] milliseconds; P &lt; .001) and ECV (mean [SD], 0.47 [0.07] vs 0.42 [0.08]; P &lt; .001). At 12 months, an increased native T1 occurred in 24 patients (15%), most of whom had a poor hematological response (17 [71%]), and was associated with an increased N-terminal pro-brain natriuretic peptide (median [IQR], 1622 [554-5487] vs 3150 [1161-8745] ng/L; P = .007), reduced left ventricular ejection fraction (mean [SD], 65.8% [11.4%] vs 61.5% [12.4%]; P = .009), and an increase in both myocardial T2 (mean [SD], 52.5 [2.7] vs 55.3 [4.2] milliseconds; P &lt; .001) and ECV (mean [SD], 0.48 [0.09] vs 0.56 [0.09]; P &lt; .001). Change in myocardial native T1 at 6 months was independently associated with mortality (hazard ratio, 2.41 [95% CI, 1.36-4.27]; P = .003).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Changes in native T1 in response to treatment, reflecting a composite of changes in T2 and ECV, are associated with in changes in traditional markers of cardiac response and associated with mortality. However, as a single-center study, these results require external validation in a larger cohort.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37466990/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720062954&v=2.17.9.post6+86293ac">37466990</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2010>10.1001/jamacardio.2023.2010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37466990</guid>
<pubDate>Wed, 19 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Adam Ioannou</dc:creator>
<dc:creator>Rishi K Patel</dc:creator>
<dc:creator>Ana Martinez-Naharro</dc:creator>
<dc:creator>Yousuf Razvi</dc:creator>
<dc:creator>Aldostefano Porcari</dc:creator>
<dc:creator>Muhammad U Rauf</dc:creator>
<dc:creator>Roos E Bolhuis</dc:creator>
<dc:creator>Jacob Fernando-Sayers</dc:creator>
<dc:creator>Ruta Virsinskaite</dc:creator>
<dc:creator>Francesco Bandera</dc:creator>
<dc:creator>Tushar Kotecha</dc:creator>
<dc:creator>Lucia Venneri</dc:creator>
<dc:creator>Daniel Knight</dc:creator>
<dc:creator>Charlotte Manisty</dc:creator>
<dc:creator>James Moon</dc:creator>
<dc:creator>Helen Lachmann</dc:creator>
<dc:creator>Carol Whelan</dc:creator>
<dc:creator>Peter Kellman</dc:creator>
<dc:creator>Philip N Hawkins</dc:creator>
<dc:creator>Julian D Gillmore</dc:creator>
<dc:creator>Ashutosh Wechalekar</dc:creator>
<dc:creator>Marianna Fontana</dc:creator>
<dc:date>2023-07-19</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Tracking Treatment Response in Cardiac Light-Chain Amyloidosis With Native T1 Mapping</dc:title>
<dc:identifier>pmid:37466990</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2010</dc:identifier>
</item>
<item>
<title>Imaging Biomarkers in the Management of Light-Chain Cardiac Amyloidosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37466953/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720062954&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Jul 19. doi: 10.1001/jamacardio.2023.2030. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37466953/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720062954&v=2.17.9.post6+86293ac">37466953</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2030>10.1001/jamacardio.2023.2030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37466953</guid>
<pubDate>Wed, 19 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Sarah A M Cuddy</dc:creator>
<dc:date>2023-07-19</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Imaging Biomarkers in the Management of Light-Chain Cardiac Amyloidosis</dc:title>
<dc:identifier>pmid:37466953</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2030</dc:identifier>
</item>
<item>
<title>Left Ventricular Dysfunction Associated With Brain Death: Results From the Donor Heart Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37465972/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720062954&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: LV dysfunction associated with brain death occurs in many potential heart donors and is sometimes reversible. These findings can inform decisions made during donor evaluation and help guide donor heart acceptance for transplantation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Jul 19. doi: 10.1161/CIRCULATIONAHA.122.063400. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Left ventricular dysfunction in potential donors meeting brain death criteria often results in nonuse of donor hearts for transplantation, yet little is known about its incidence or pathophysiology. Resolving these unknowns was a primary aim of the DHS (Donor Heart Study), a multisite prospective cohort study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The DHS enrolled potential donors by neurologic determination of death (n=4333) at 8 organ procurement organizations across the United States between February 2015 and May 2020. Data included medications administered, serial diagnostic tests, and transthoracic echocardiograms (TTEs) performed: (1) within 48 hours after brain death was formally diagnosed; and (2) 24±6 hours later if left ventricular (LV) dysfunction was initially present. LV dysfunction was defined as an LV ejection fraction &lt;50% and was considered reversible if LV ejection fraction was >;50% on the second TTE. TTEs were also examined for presence of LV regional wall motion abnormalities and their reversibility. We assessed associations between LV dysfunction, donor heart acceptance for transplantation, and recipient 1-year survival.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: An initial TTE was interpreted for 3794 of the 4333 potential donors by neurologic determination of death. A total of 493 (13%) of these TTEs showed LV dysfunction. Among those donors with an initial TTE, LV dysfunction was associated with younger age, underweight, and higher NT-proBNP (N-terminal pro-B-type natriuretic peptide) and troponin levels. A second TTE was performed within 24±6 hours for a subset of donors (n=224) with initial LV dysfunction; within this subset, 130 (58%) demonstrated reversibility. Sixty percent of donor hearts with normal LV function were accepted for transplant compared with 56% of hearts with reversible LV dysfunction and 24% of hearts with nonreversible LV dysfunction. Donor LV dysfunction, whether reversible or not, was not associated with recipient 1-year survival.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: LV dysfunction associated with brain death occurs in many potential heart donors and is sometimes reversible. These findings can inform decisions made during donor evaluation and help guide donor heart acceptance for transplantation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37465972/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720062954&v=2.17.9.post6+86293ac">37465972</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063400>10.1161/CIRCULATIONAHA.122.063400</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37465972</guid>
<pubDate>Wed, 19 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Kiran K Khush</dc:creator>
<dc:creator>Darren Malinoski</dc:creator>
<dc:creator>Helen Luikart</dc:creator>
<dc:creator>Brian Wayda</dc:creator>
<dc:creator>Tahnee Groat</dc:creator>
<dc:creator>John Nguyen</dc:creator>
<dc:creator>John Belcher</dc:creator>
<dc:creator>Javier Nieto</dc:creator>
<dc:creator>Nikole Neidlinger</dc:creator>
<dc:creator>Ahmad Salehi</dc:creator>
<dc:creator>P J Geraghty</dc:creator>
<dc:creator>Bruce Nicely</dc:creator>
<dc:creator>Martin Jendrisak</dc:creator>
<dc:creator>Thomas Pearson</dc:creator>
<dc:creator>R Patrick Wood</dc:creator>
<dc:creator>Shiqi Zhang</dc:creator>
<dc:creator>Yingjie Weng</dc:creator>
<dc:creator>Jonathan Zaroff</dc:creator>
<dc:date>2023-07-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Left Ventricular Dysfunction Associated With Brain Death: Results From the Donor Heart Study</dc:title>
<dc:identifier>pmid:37465972</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.063400</dc:identifier>
</item>
<item>
<title>Intravascular imaging during percutaneous coronary intervention: temporal trends and clinical outcomes in the USA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37464975/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720062954&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSION: Among Medicare beneficiaries undergoing PCI, use of IVI has increased over the previous decade but remains relatively infrequent. IVI-guided PCI was associated with lower risk-adjusted mortality, acute MI, repeat PCI, and MACE.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Jul 19:ehad430. doi: 10.1093/eurheartj/ehad430. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">AIMS: Prior trials have demonstrated that intravascular imaging (IVI)-guided percutaneous coronary intervention (PCI) results in less frequent target lesion revascularization and major adverse cardiovascular events (MACEs) compared with standard angiographic guidance. The uptake and associated outcomes of IVI-guided PCI in contemporary clinical practice in the USA remain unclear. Accordingly, temporal trends and comparative outcomes of IVI-guided PCI relative to PCI with angiographic guidance alone were examined in a broad, unselected population of Medicare beneficiaries.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS AND RESULTS: Retrospective cohort study of Medicare beneficiary data from 1 January 2013, through 31 December 2019 to evaluate temporal trends and comparative outcomes of IVI-guided PCI as compared with PCI with angiography guidance alone in both the inpatient and outpatient settings. The primary outcomes were 1 year mortality and MACE, defined as the composite of death, myocardial infarction (MI), repeat PCI, or coronary artery bypass graft surgery. Secondary outcomes were MI or repeat PCI at 1 year. Multivariable Cox regression was used to estimate the adjusted association between IVI guidance and outcomes. Falsification endpoints (hospitalized pneumonia and hip fracture) were used to assess for potential unmeasured confounding. The study population included 1 189 470 patients undergoing PCI (38.0% female, 89.8% White, 65.1% with MI). Overall, IVI was used in 10.5% of the PCIs, increasing from 9.5% in 2013% to 15.4% in 2019. Operator IVI use was variable, with the median operator use of IVI 3.92% (interquartile range 0.36%-12.82%). IVI use during PCI was associated with lower adjusted rates of 1 year mortality [adjusted hazard ratio (aHR) 0.96, 95% confidence interval (CI) 0.94-0.98], MI (aHR 0.97, 95% CI 0.95-0.99), repeat PCI (aHR 0.74, 95% CI 0.73-0.75), and MACE (aHR 0.85, 95% CI 0.84-0.86). There was no association with the falsification endpoint of hospitalized pneumonia (aHR 1.02, 95% CI 0.99-1.04) or hip fracture (aHR 1.02, 95% CI 0.94-1.10).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: Among Medicare beneficiaries undergoing PCI, use of IVI has increased over the previous decade but remains relatively infrequent. IVI-guided PCI was associated with lower risk-adjusted mortality, acute MI, repeat PCI, and MACE.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37464975/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720062954&v=2.17.9.post6+86293ac">37464975</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad430>10.1093/eurheartj/ehad430</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37464975</guid>
<pubDate>Wed, 19 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Reza Fazel</dc:creator>
<dc:creator>Robert W Yeh</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>Sunil V Rao</dc:creator>
<dc:creator>Siling Li</dc:creator>
<dc:creator>Yang Song</dc:creator>
<dc:creator>Eric A Secemsky</dc:creator>
<dc:date>2023-07-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intravascular imaging during percutaneous coronary intervention: temporal trends and clinical outcomes in the USA</dc:title>
<dc:identifier>pmid:37464975</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad430</dc:identifier>
</item>
<item>
<title>Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37464183/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720062954&amp;v=2.17.9.post6+86293ac
      <description>Artificial intelligence (AI) is likely to revolutionize the way medical images are analysed and has the potential to improve the identification and analysis of vulnerable or high-risk atherosclerotic plaques in coronary arteries, leading to advances in the treatment of coronary artery disease. However, coronary plaque analysis is challenging owing to cardiac and respiratory motion, as well as the small size of cardiovascular structures. Moreover, the analysis of coronary imaging data is...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Jul 18. doi: 10.1038/s41569-023-00900-3. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Artificial intelligence (AI) is likely to revolutionize the way medical images are analysed and has the potential to improve the identification and analysis of vulnerable or high-risk atherosclerotic plaques in coronary arteries, leading to advances in the treatment of coronary artery disease. However, coronary plaque analysis is challenging owing to cardiac and respiratory motion, as well as the small size of cardiovascular structures. Moreover, the analysis of coronary imaging data is time-consuming, can be performed only by clinicians with dedicated cardiovascular imaging training, and is subject to considerable interreader and intrareader variability. AI has the potential to improve the assessment of images of vulnerable plaque in coronary arteries, but requires robust development, testing and validation. Combining human expertise with AI might facilitate the reliable and valid interpretation of images obtained using CT, MRI, PET, intravascular ultrasonography and optical coherence tomography. In this Roadmap, we review existing evidence on the application of AI to the imaging of vulnerable plaque in coronary arteries and provide consensus recommendations developed by an interdisciplinary group of experts on AI and non-invasive and invasive coronary imaging. We also outline future requirements of AI technology to address bias, uncertainty, explainability and generalizability, which are all essential for the acceptance of AI and its clinical utility in handling the anticipated growing volume of coronary imaging procedures.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37464183/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720062954&v=2.17.9.post6+86293ac">37464183</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00900-3>10.1038/s41569-023-00900-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37464183</guid>
<pubDate>Tue, 18 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Bernhard Föllmer</dc:creator>
<dc:creator>Michelle C Williams</dc:creator>
<dc:creator>Damini Dey</dc:creator>
<dc:creator>Armin Arbab-Zadeh</dc:creator>
<dc:creator>Pál Maurovich-Horvat</dc:creator>
<dc:creator>Rick H J A Volleberg</dc:creator>
<dc:creator>Daniel Rueckert</dc:creator>
<dc:creator>Julia A Schnabel</dc:creator>
<dc:creator>David E Newby</dc:creator>
<dc:creator>Marc R Dweck</dc:creator>
<dc:creator>Giulio Guagliumi</dc:creator>
<dc:creator>Volkmar Falk</dc:creator>
<dc:creator>Aldo J Vázquez Mézquita</dc:creator>
<dc:creator>Federico Biavati</dc:creator>
<dc:creator>Ivana Išgum</dc:creator>
<dc:creator>Marc Dewey</dc:creator>
<dc:date>2023-07-18</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries</dc:title>
<dc:identifier>pmid:37464183</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00900-3</dc:identifier>
</item>
<item>
<title>Microstructural and Microvascular Phenotype of Sarcomere Mutation Carriers and Overt Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37463608/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720062954&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Microstructural alteration and MVD occur in overt HCM and are different in G+ and G- patients. Both also occur in the absence of hypertrophy in sarcomeric mutation carriers, in whom changes are associated with electrocardiographic abnormalities. Measurable changes in myocardial microstructure and microvascular function are early-phenotype biomarkers in the emerging era of disease-modifying therapy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Jul 18. doi: 10.1161/CIRCULATIONAHA.123.063835. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In hypertrophic cardiomyopathy (HCM), myocyte disarray and microvascular disease (MVD) have been implicated in adverse events, and recent evidence suggests that these may occur early. As novel therapy provides promise for disease modification, detection of phenotype development is an emerging priority. To evaluate their utility as early and disease-specific biomarkers, we measured myocardial microstructure and MVD in 3 HCM groups-overt, either genotype-positive (G+LVH+) or genotype-negative (G-LVH+), and subclinical (G+LVH-) HCM-exploring relationships with electrical changes and genetic substrate.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a multicenter collaboration to study 206 subjects: 101 patients with overt HCM (51 G+LVH+ and 50 G-LVH+), 77 patients with G+LVH-, and 28 matched healthy volunteers. All underwent 12-lead ECG, quantitative perfusion cardiac magnetic resonance imaging (measuring myocardial blood flow, myocardial perfusion reserve, and perfusion defects), and cardiac diffusion tensor imaging measuring fractional anisotropy (lower values expected with more disarray), mean diffusivity (reflecting myocyte packing/interstitial expansion), and second eigenvector angle (measuring sheetlet orientation).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Compared with healthy volunteers, patients with overt HCM had evidence of altered microstructure (lower fractional anisotropy, higher mean diffusivity, and higher second eigenvector angle; all <i>P</i>&lt;0.001) and MVD (lower stress myocardial blood flow and myocardial perfusion reserve; both <i>P</i>&lt;0.001). Patients with G-LVH+ were similar to those with G+LVH+ but had elevated second eigenvector angle (<i>P</i>&lt;0.001 after adjustment for left ventricular hypertrophy and fibrosis). In overt disease, perfusion defects were found in all G+ but not all G- patients (100% [51/51] versus 82% [41/50]; <i>P</i>=0.001). Patients with G+LVH- compared with healthy volunteers similarly had altered microstructure, although to a lesser extent (all diffusion tensor imaging parameters; <i>P</i>&lt;0.001), and MVD (reduced stress myocardial blood flow [<i>P</i>=0.015] with perfusion defects in 28% versus 0 healthy volunteers [<i>P</i>=0.002]). Disarray and MVD were independently associated with pathological electrocardiographic abnormalities in both overt and subclinical disease after adjustment for fibrosis and left ventricular hypertrophy (overt: fractional anisotropy: odds ratio for an abnormal ECG, 3.3, <i>P</i>=0.01; stress myocardial blood flow: odds ratio, 2.8, <i>P</i>=0.015; subclinical: fractional anisotropy odds ratio, 4.0, <i>P</i>=0.001; myocardial perfusion reserve odds ratio, 2.2, <i>P</i>=0.049).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Microstructural alteration and MVD occur in overt HCM and are different in G+ and G- patients. Both also occur in the absence of hypertrophy in sarcomeric mutation carriers, in whom changes are associated with electrocardiographic abnormalities. Measurable changes in myocardial microstructure and microvascular function are early-phenotype biomarkers in the emerging era of disease-modifying therapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37463608/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720062954&v=2.17.9.post6+86293ac">37463608</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.063835>10.1161/CIRCULATIONAHA.123.063835</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37463608</guid>
<pubDate>Tue, 18 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>George Joy</dc:creator>
<dc:creator>Christopher I Kelly</dc:creator>
<dc:creator>Matthew Webber</dc:creator>
<dc:creator>Iain Pierce</dc:creator>
<dc:creator>Irvin Teh</dc:creator>
<dc:creator>Louise McGrath</dc:creator>
<dc:creator>Paula Velazquez</dc:creator>
<dc:creator>Rebecca K Hughes</dc:creator>
<dc:creator>Huafrin Kotwal</dc:creator>
<dc:creator>Arka Das</dc:creator>
<dc:creator>Fiona Chan</dc:creator>
<dc:creator>Athanasios Bakalakos</dc:creator>
<dc:creator>Massimiliano Lorenzini</dc:creator>
<dc:creator>Konstantinos Savvatis</dc:creator>
<dc:creator>Sam A Mohiddin</dc:creator>
<dc:creator>Peter W Macfarlane</dc:creator>
<dc:creator>Michele Orini</dc:creator>
<dc:creator>Charlotte Manisty</dc:creator>
<dc:creator>Peter Kellman</dc:creator>
<dc:creator>Rhodri H Davies</dc:creator>
<dc:creator>Pier D Lambiase</dc:creator>
<dc:creator>Christopher Nguyen</dc:creator>
<dc:creator>Jurgen E Schneider</dc:creator>
<dc:creator>Maite Tomé</dc:creator>
<dc:creator>Gabriella Captur</dc:creator>
<dc:creator>Erica Dall'Armellina</dc:creator>
<dc:creator>James C Moon</dc:creator>
<dc:creator>Luis R Lopes</dc:creator>
<dc:date>2023-07-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Microstructural and Microvascular Phenotype of Sarcomere Mutation Carriers and Overt Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:37463608</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.063835</dc:identifier>
</item>
<item>
<title>Impact of Complete Revascularization in the ISCHEMIA Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37462593/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720062954&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: The outcomes of an INV strategy may be improved if CR (especially ACR) is achieved. (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches [ISCHEMIA]; NCT01471522).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Jul 11:S0735-1097(23)06031-X. doi: 10.1016/j.jacc.2023.06.015. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Anatomic complete revascularization (ACR) and functional complete revascularization (FCR) have been associated with reduced death and myocardial infarction (MI) in some prior studies. The impact of complete revascularization (CR) in patients undergoing an invasive (INV) compared with a conservative (CON) management strategy has not been reported.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: Among patients with chronic coronary disease without prior coronary artery bypass grafting randomized to INV vs CON management in the ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial, we examined the following: 1) the outcomes of ACR and FCR compared with incomplete revascularization; and 2) the potential impact of achieving CR in all INV patients compared with CON management.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: ACR and FCR in the INV group were assessed at an independent core laboratory. Multivariable-adjusted outcomes of CR were examined in INV patients. Inverse probability weighted modeling was then performed to estimate the treatment effect had CR been achieved in all INV patients compared with CON management.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: ACR and FCR were achieved in 43.4% and 58.4% of 1,824 INV patients. ACR was associated with reduced 4-year rates of cardiovascular death or MI compared with incomplete revascularization. By inverse probability weighted modeling, ACR in all 2,296 INV patients compared with 2,498 CON patients was associated with a lower 4-year rate of cardiovascular death or MI (difference -3.5; 95% CI: -7.2% to 0.0%). In comparison, the event rate difference of cardiovascular death or MI for INV minus CON in the overall ISCHEMIA trial was -2.4%. Results were similar but less pronounced with FCR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The outcomes of an INV strategy may be improved if CR (especially ACR) is achieved. (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches [ISCHEMIA]; NCT01471522).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37462593/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720062954&v=2.17.9.post6+86293ac">37462593</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.015>10.1016/j.jacc.2023.06.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37462593</guid>
<pubDate>Tue, 18 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Ziad A Ali</dc:creator>
<dc:creator>Sean M O'Brien</dc:creator>
<dc:creator>Grace Rhodes</dc:creator>
<dc:creator>Philippe Genereux</dc:creator>
<dc:creator>Sripal Bangalore</dc:creator>
<dc:creator>Kreton Mavromatis</dc:creator>
<dc:creator>Jennifer Horst</dc:creator>
<dc:creator>Ovidiu Dressler</dc:creator>
<dc:creator>Kian Keong Poh</dc:creator>
<dc:creator>Ranjit K Nath</dc:creator>
<dc:creator>Nagaraja Moorthy</dc:creator>
<dc:creator>Adam Witkowski</dc:creator>
<dc:creator>Sudhanshu K Dwivedi</dc:creator>
<dc:creator>Olga Bockeria</dc:creator>
<dc:creator>Jiyan Chen</dc:creator>
<dc:creator>Paola E P Smanio</dc:creator>
<dc:creator>Michael H Picard</dc:creator>
<dc:creator>Bernard R Chaitman</dc:creator>
<dc:creator>Daniel S Berman</dc:creator>
<dc:creator>Leslee J Shaw</dc:creator>
<dc:creator>William E Boden</dc:creator>
<dc:creator>Harvey D White</dc:creator>
<dc:creator>Stephen E Fremes</dc:creator>
<dc:creator>Yves Rosenberg</dc:creator>
<dc:creator>Harmony R Reynolds</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Judith S Hochman</dc:creator>
<dc:creator>David J Maron</dc:creator>
<dc:creator>ISCHEMIA Research Group</dc:creator>
<dc:date>2023-07-18</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Impact of Complete Revascularization in the ISCHEMIA Trial</dc:title>
<dc:identifier>pmid:37462593</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.015</dc:identifier>
</item>
<item>
<title>Brown Adipose Tissue and BMP3b Decrease Injury in Cardiac Ischemia-Reperfusion</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37462036/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720062954&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: The results of this study suggest a cardioprotective role of BAT and BMP3b, a protein secreted by BAT, in a model of I/R injury. Interventions increasing BMP3b levels or targeting Smad 1/5 may represent novel therapeutic approaches to decrease myocardial damage in I/R injury.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Jul 18. doi: 10.1161/CIRCRESAHA.122.322337. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Despite advances in treatment, myocardial infarction (MI) is a leading cause of heart failure and death worldwide, with both ischemia and reperfusion (I/R) causing cardiac injury. A previous study using a mouse model of nonreperfused MI showed activation of brown adipose tissue (BAT). Recent studies showed that molecules secreted by BAT target the heart. We investigated whether BAT attenuates cardiac injury in I/R and sought to identify potential cardioprotective proteins secreted by BAT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Myocardial I/R surgery with or without BAT transplantation was performed in wild-type (WT) mice and in mice with impaired BAT function (uncoupling protein 1 [<i>Ucp1</i>]-deficient mice). To identify potential cardioprotective factors produced by BAT, RNA-seq was performed in BAT from WT and <i>Ucp1</i><sup><i>-</i></sup><sup><i>/-</i></sup> mice. Subsequently, myocardial I/R surgery with or without BAT transplantation was performed in <i>Bmp3b</i> (bone morphogenetic protein 3b)-deficient mice, and WT mice subjected to myocardial I/R were treated using BMP3b.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Dysfunction of BAT in mice was associated with larger MI size after I/R; conversely, augmenting BAT by transplantation decreased MI size. We identified Bmp3b as a protein secreted by BAT after I/R. Compared with WT mice, <i>Bmp3b</i>-deficient mice developed larger MIs. Increasing functional BAT by transplanting BAT from WT mice to <i>Bmp3b</i>-deficient mice reduced I/R injury whereas transplanting BAT from <i>Bmp3b</i>-deficient mice did not. Treatment of WT mice with BMP3b before reperfusion decreased MI size. The cardioprotective effect of BMP3b was mediated through SMAD1/5/8. In humans, the plasma level of BMP3b increased after MI and was positively correlated with the extent of cardiac injury.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The results of this study suggest a cardioprotective role of BAT and BMP3b, a protein secreted by BAT, in a model of I/R injury. Interventions increasing BMP3b levels or targeting Smad 1/5 may represent novel therapeutic approaches to decrease myocardial damage in I/R injury.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37462036/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720062954&v=2.17.9.post6+86293ac">37462036</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.122.322337>10.1161/CIRCRESAHA.122.322337</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37462036</guid>
<pubDate>Tue, 18 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Íngrid Martí-Pàmies</dc:creator>
<dc:creator>Robrecht Thoonen</dc:creator>
<dc:creator>Michael Morley</dc:creator>
<dc:creator>Lauren Graves</dc:creator>
<dc:creator>Jesus Tamez</dc:creator>
<dc:creator>Alex Caplan</dc:creator>
<dc:creator>Kendra McDaid</dc:creator>
<dc:creator>Vincent Yao</dc:creator>
<dc:creator>Allyson Hindle</dc:creator>
<dc:creator>Robert E Gerszten</dc:creator>
<dc:creator>Laurie A Farrell</dc:creator>
<dc:creator>Li Li</dc:creator>
<dc:creator>Yu-Hua Tseng</dc:creator>
<dc:creator>Gerson Profeta</dc:creator>
<dc:creator>Emmanuel S Buys</dc:creator>
<dc:creator>Donald B Bloch</dc:creator>
<dc:creator>Marielle Scherrer-Crosbie</dc:creator>
<dc:date>2023-07-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Brown Adipose Tissue and BMP3b Decrease Injury in Cardiac Ischemia-Reperfusion</dc:title>
<dc:identifier>pmid:37462036</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.122.322337</dc:identifier>
</item>
<item>
<title>Chylomicrons Regulate Lacteal Permeability and Intestinal Lipid Absorption</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37462027/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720062954&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Our results reveal that antagonistic inputs into ROCK-dependent cytoskeleton contractions regulate the interconversion of lymphatic junctions in the intestine and in other tissues, providing a tunable mechanism to control the lymphatic barrier.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Jul 18. doi: 10.1161/CIRCRESAHA.123.322607. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Lymphatic vessels are responsible for tissue drainage, and their malfunction is associated with chronic diseases. Lymph uptake occurs via specialized open cell-cell junctions between capillary lymphatic endothelial cells (LECs), whereas closed junctions in collecting LECs prevent lymph leakage. LEC junctions are known to dynamically remodel in development and disease, but how lymphatic permeability is regulated remains poorly understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used various genetically engineered mouse models in combination with cellular, biochemical, and molecular biology approaches to elucidate the signaling pathways regulating junction morphology and function in lymphatic capillaries.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: By studying the permeability of intestinal lacteal capillaries to lipoprotein particles known as chylomicrons, we show that ROCK (Rho-associated kinase)-dependent cytoskeletal contractility is a fundamental mechanism of LEC permeability regulation. We show that chylomicron-derived lipids trigger neonatal lacteal junction opening via ROCK-dependent contraction of junction-anchored stress fibers. LEC-specific ROCK deletion abolished junction opening and plasma lipid uptake. Chylomicrons additionally inhibited VEGF (vascular endothelial growth factor)-A signaling. We show that VEGF-A antagonizes LEC junction opening via VEGFR (VEGF receptor) 2 and VEGFR3-dependent PI3K/AKT activation of the small GTPase RAC1, thereby restricting RhoA/ROCK-mediated cytoskeleton contraction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our results reveal that antagonistic inputs into ROCK-dependent cytoskeleton contractions regulate the interconversion of lymphatic junctions in the intestine and in other tissues, providing a tunable mechanism to control the lymphatic barrier.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37462027/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720062954&v=2.17.9.post6+86293ac">37462027</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322607>10.1161/CIRCRESAHA.123.322607</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37462027</guid>
<pubDate>Tue, 18 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Georgia Zarkada</dc:creator>
<dc:creator>Xun Chen</dc:creator>
<dc:creator>Xuetong Zhou</dc:creator>
<dc:creator>Martin Lange</dc:creator>
<dc:creator>Lei Zeng</dc:creator>
<dc:creator>Wenyu Lv</dc:creator>
<dc:creator>Xuan Zhang</dc:creator>
<dc:creator>Yunhua Li</dc:creator>
<dc:creator>Weibin Zhou</dc:creator>
<dc:creator>Keli Liu</dc:creator>
<dc:creator>Dongying Chen</dc:creator>
<dc:creator>Nicolas Ricard</dc:creator>
<dc:creator>James Liao</dc:creator>
<dc:creator>Young-Bum Kim</dc:creator>
<dc:creator>Rui Benedito</dc:creator>
<dc:creator>Lena Claesson-Welsh</dc:creator>
<dc:creator>Kari Alitalo</dc:creator>
<dc:creator>Michael Simons</dc:creator>
<dc:creator>Rong Ju</dc:creator>
<dc:creator>Xuri Li</dc:creator>
<dc:creator>Anne Eichmann</dc:creator>
<dc:creator>Feng Zhang</dc:creator>
<dc:date>2023-07-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Chylomicrons Regulate Lacteal Permeability and Intestinal Lipid Absorption</dc:title>
<dc:identifier>pmid:37462027</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322607</dc:identifier>
</item>
<item>
<title>Diagnosis and Management of Cardiovascular Risk in Individuals With Spinal Cord Injury: A Narrative Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37459417/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230720062954&amp;v=2.17.9.post6+86293ac
      <description>More than 16 000 Americans experience spinal cord injury (SCI), resulting in chronic disability and other secondary sequelae, each year. Improvements in acute medical management have increased life expectancy. Cardiovascular disease is a leading cause of death in this population, and seems to occur earlier in individuals with SCI compared with the general population. People with SCI experience a high burden of traditional cardiovascular disease risk factors, including dyslipidemia and diabetes,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Jul 18;148(3):268-277. doi: 10.1161/CIRCULATIONAHA.123.064859. Epub 2023 Jul 17.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">More than 16 000 Americans experience spinal cord injury (SCI), resulting in chronic disability and other secondary sequelae, each year. Improvements in acute medical management have increased life expectancy. Cardiovascular disease is a leading cause of death in this population, and seems to occur earlier in individuals with SCI compared with the general population. People with SCI experience a high burden of traditional cardiovascular disease risk factors, including dyslipidemia and diabetes, and demonstrate anatomic, metabolic, and physiologic changes alongside stark reductions in physical activity after injury. They also experience multiple, complex barriers to care relating to disability and, in many cases, compounding effects of intersecting racial and socioeconomic health inequities. Given this combination of risk factors, some investigators have proposed that people with SCI are at increased risk for cardiovascular disease, beyond that associated with traditional risk factors, and SCI could be considered a risk-enhancing factor, analogous to other risk-enhancing factors defined by the 2019 American Heart Association/American College of Cardiology Primary Prevention Guidelines. However, more research is needed in this population to clarify the role of traditional risk factors, novel risk factors, health care access, social determinants of health, and intersectionality of disability, race, and socioeconomic status. There is an urgent need for primary care physicians and cardiologists to have awareness of the importance of timely diagnosis and management of cardiac risk factors for people with SCI.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37459417/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230720062954&v=2.17.9.post6+86293ac">37459417</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064859>10.1161/CIRCULATIONAHA.123.064859</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37459417</guid>
<pubDate>Mon, 17 Jul 2023 06:00:00 -0400</pubDate>
<dc:creator>Tara Lagu</dc:creator>
<dc:creator>Samantha L Schroth</dc:creator>
<dc:creator>Carol Haywood</dc:creator>
<dc:creator>Allen Heinemann</dc:creator>
<dc:creator>Allison Kessler</dc:creator>
<dc:creator>Leslie Morse</dc:creator>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Kiarri N Kershaw</dc:creator>
<dc:creator>Mark S Nash</dc:creator>
<dc:date>2023-07-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Diagnosis and Management of Cardiovascular Risk in Individuals With Spinal Cord Injury: A Narrative Review</dc:title>
<dc:identifier>pmid:37459417</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064859</dc:identifier>
</item>





























</channel>
</rss>